Article
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Mar 2011
Arcila Maria E, Oxnard Geoffrey R, Nafa Khedoudja, Riely Gregory J, Solomon Stephen B, Zakowski Maureen F, Kris Mark G, Pao William, Miller Vincent A, Ladanyi Marc
Abstract excerpt
BACKGROUND: The epidermal growth factor receptor (EGFR) mutation T790M is reported in approximately 50% of lung cancers with acquired resistance to EGFR inhibitors and is a potential prognostic and predictive biomarker. Its assessment can be challenging due to limited tissue availability and underdetection at low mutant allele levels. Here, we sought to determine the feasibility of tumor rebiopsy and to more...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.